Murine Acquired Immunodeficiency Syndrome (MAIDS)

Acquired defect of cellular immunity that occurs in mice infected with mouse leukemia viruses (MuLV). The syndrome shows striking similarities with human AIDS and is characterized by lymphadenopathy, profound immunosuppression, enhanced susceptibility to opportunistic infections, and B-cell lymphomas.

Also Known As:

Networked: 260 relevant articles (17 outcomes, 31 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Acquired Immunodeficiency Syndrome (AIDS)
3.	Retinitis
4.	Splenomegaly
5.	Hypergammaglobulinemia (Hyperimmunoglobulinemia)

Experts

1.	Dix, Richard D: 7 articles (03/2013 - 03/2003)
2.	Watson, Ronald R: 7 articles (01/2011 - 01/2002)
3.	Green, William R: 5 articles (01/2013 - 03/2003)
4.	Magnani, M: 5 articles (02/2009 - 03/2000)
5.	Fraternale, A: 5 articles (02/2009 - 03/2000)
6.	Casabianca, A: 5 articles (02/2009 - 03/2000)
7.	Cousins, Scott W: 5 articles (10/2004 - 03/2003)
8.	Davis-Gorman, Grace: 5 articles (03/2003 - 01/2002)
9.	McDonagh, Paul F: 5 articles (03/2003 - 01/2002)
10.	Chen, Yinhong: 5 articles (03/2003 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Murine Acquired Immunodeficiency Syndrome:

1.	Interleukin-2 (IL2)IBA 06/01/1993 - "A murine acquired immunodeficiency (MAIDS) virus transformed B cell line, B6-1710, was shown to express superantigen activity and stimulate T cell hybridomas to produce IL-2. " 03/01/1993 - "A B cell line, B6-1710, expressing murine AIDS virus superantigen stimulates T cell hybridomas derived from a Ld-specific CTL clone to produce IL-2 regardless of their CD4/CD8 phenotype. " 05/01/2003 - "However, IL-2 immunotherapy during MAIDS had no appreciable effect on the number of NK cells that infiltrated MCMV-infected eyes. " 05/01/2003 - "We have shown previously that systemic cytokine immunotherapy with interleukin-2 (IL-2) will protect against experimental murine cytomegalovirus (MCMV) in mice with a murine retrovirus-induced immunodeficiency syndrome (MAIDS). " 07/01/2003 - "Experiments were performed to explore the mechanism by which IL-2 treatment during MAIDS might restore resistance to MCMV retinitis. "
2.	PerforinIBA 03/01/1997 - "These results demonstrate that perforin-dependent functions of CD8+ T cells contribute to MAIDS resistance but that other, non-CD8-dependent mechanisms are of equal or greater importance." 03/01/1997 - "To further evaluate the mechanisms contributing to MAIDS resistance, we studied mice lacking CD8+ T cells or deficient in perforin due to knockout of the beta2-microglobulin (beta2M) or perforin gene, respectively. " 11/01/2004 - "Perforin knockout mice, but not mice with MAIDS, show protection against experimental cytomegalovirus retinitis after adoptive transfer of immune cells with a functional perforin cytotoxic pathway." 03/01/2003 - "Since mice with retrovirus-induced immunodeficiency syndrome (MAIDS) exhibited a frequency and severity of MCMV retinitis that were equivalent to those observed in PKO mice, we hypothesized that susceptibility to MCMV retinitis during MAIDS correlates with a decrease in the perforin cytotoxic pathway. " 07/01/2003 - "A competitive quantitative RT-PCR assay was used to measure the levels of perforin mRNA within MCMV-infected eyes of immunologically normal mice, untreated MAIDS mice, and IL-2-treated MAIDS mice. "
3.	Ethanol (Ethyl Alcohol)IBA 11/01/2002 - "Chronic ethanol consumption did not alter coronary permeability to macromolecules, but improved the coronary haemodynamics in murine AIDS. " 11/01/2002 - "The aim of this study was to assess the integrity of the coronary microcirculation in murine AIDS mice in the presence or absence of chronic ethanol consumption. " 03/01/2003 - "In the murine AIDS plus ethanol group, there were significant increases in both ROS and CD11b expression during the 3-month observation period. " 03/01/2003 - "Four groups were studied: control, murine AIDS, ethanol and ethanol plus murine AIDS. " 01/01/2003 - "Platelets were significantly activated in mice with murine AIDS and chronic ethanol consumption. "
4.	Cocaine (Cocaine HCl)IBA 01/01/1994 - "Our objective was to investigate if cocaine treatment could alter the mucosal immune system at the level of the intestinal lamina propria (ILP) and if it could further modify the already altered mucosal immunity when it was administered to MAIDS-mice. " 01/01/1994 - "Effect of cocaine and murine AIDS on lamina propria T and B cells in normal mice." 01/01/1993 - "However, due to the very slow progression to murine AIDS in the males, parasite resistance was retained, including in cocaine treated C57BL-6 mice. " 12/01/1991 - "The effects of cocaine and murine AIDS on natural killer (NK) cell activity in C57BL/6 mice was studied. " 07/01/2003 - "The present study uses cocaine treatment of an established murine AIDS transgenic model (NL4-3Delta gag/pol; TG) to define the combined effects of AIDS and cocaine on cardiac pathophysiology. "
5.	Interleukin-12 (IL 12)IBA 09/01/1997 - "This study indicates that once anergy has been established in MAIDS, it cannot be reversed by providing costimulation via CD28 and IL-12. " 04/01/1999 - "The role of IL-12 in the control of MCMV is fundamentally different in mice with a retroviral immunodeficiency syndrome (MAIDS)." 09/01/1997 - "CD4 T cell anergy in murine AIDS: costimulation via CD28 and the addition of IL-12 are not sufficient to rescue anergic CD4 T cells." 09/01/1995 - "Role of IL12 in MAIDS." 12/01/1994 - "The therapeutic effects of IL-12 on the immune system of mice with MAIDS were also associated with reduced expression of the retrovirus that causes this disease (BM5def), with lesser effects on expression of ecotropic MuLV. "
6.	AntibodiesIBA 12/01/1983 - "A panel of distinct monoclonal antiidiotype antibodies (MAIDs) was then used to examine idiotope expression by antibodies secreted in splenic foci responding to DEX and DEX-Hy. " 09/01/1983 - "Although both IdX and IdI MAIDs were obtained, IdI specific antibodies were obtained more frequently. " 09/01/1983 - "The predominant heavy chain isotype of these MAIDs was gamma 1. These antibodies were used to identify individual idiotypic structures (IdI) on J558, or M104E as well as cross-reactive determinants common to both (IdX). " 09/01/1983 - "Monoclonal syngeneic and allogeneic anti-idiotype antibodies (MAIDs) specific for anti-DEX antibodies were used in this study to dissect the serum antibody response to DEX in BALB/c mice. " 01/01/1983 - "Panels of monoclonal anti-idiotype antibodies (MAIDs) specific for individual (IdI) and cross-reactive (IdX) idiotopes were prepared and used to study the expression of these idiotopes on anti-DEX and anti-PC antibodies produced in response to antigenic stimulation in vivo, clonal expression of idiotopes in an in vitro splenic focus assay, and the alterations in the idiotypic profile of these responses after in vivo administration of monoclonal anti-Id antibodies. "
7.	DNA (Deoxyribonucleic Acid)IBA 05/01/2002 - "Subsequent RT-PCR and DNA sequencing analyses confirmed the transient up-regulation of retroviral sequences similar to those of the MAIDS virus. " 04/15/1994 - "E alpha d-mediated resistance to MAIDS was associated with decreased levels of the BM5def genome in splenic DNA, suggesting that E alpha genes exert their effect by enhancing antiviral activity." 05/01/2002 - "These data suggest that the transcriptional efficiency of the integrated retroviral DNA and reactivation of defective MAIDS virus-related sequences may be affected by pathophysiological signals, such as burn injury. " 06/01/2004 - "In this study, all RRIs tested showed the ability to improve the efficacy of ABC in the MAIDS model by reducing splenomegaly, hypergammaglobulinemia, and splenic proviral DNA levels." 07/01/1996 - "The use of anion exchange HPLC to quantify the PCR product resulting from the specific amplification of the DNA from the replicative-defective viral DNA responsible for MAIDS is described. "
8.	Ribavirin (Virazole)FDA LinkGeneric 03/01/1997 - "In conclusion, treatment with ribavirin showed clear efficacy against MAIDS whereas PFA had no efficacy. " 08/15/1996 - "Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model." 08/15/1996 - "Hematotoxicity appeared at doses > or = 50 mg/kg ribavirin, and severe anemia was predominant only at doses of 100 and 200 mg/kg. This study shows that ribavirin protects mice against the effects resulting from retrovirus infection at doses of > or = 50 mg/kg in a MAIDS model and induces severe hematotoxicity at doses > or = 100 mg/kg." 03/01/1997 - "Antiviral efficacy and toxicity of ribavirin and foscarnet each given alone or in combination in the murine AIDS model." 11/01/1996 - "The efficacy and toxicity of ribavirin (25 or 125 mg/kg/day), 2',3'-dideoxyinosine (ddI) (200 mg/kg/day) and a combination of both drugs at these doses given for 6 weeks were investigated in the murine acquired immunodeficiency syndrome model. "
9.	Free RadicalsIBA 01/01/2011 - "This study suggests that certain types of ITCs have beneficial effects in preventing premature death during progression to murine AIDS by restoration of immune dysfunction and removal of excessive free radicals, implying that selective usage of ITCs would be helpful in retarding the progression from HIV infection to AIDS."
10.	Interleukin-4 (Interleukin 4)IBA 03/01/2003 - "As expected, spleen cells from mice with MAIDS expressed significantly greater levels of IL-4 when compared with spleen cells from normal mice. " 03/01/2003 - "MCMV-infected mice with MAIDS exhibited an expected preferential activation of Th2 cells as determined by increased levels of IL-4 in spleen cells when compared with spleen cells of normal mice. " 03/01/2003 - "IL-4 levels in individual spleens collected five days later from groups of MAIDS mice and normal mice were assessed by quantitative ELISA. " 05/01/1995 - "In contrast, no significant spontaneous IL-4 production and no increase in IL-4 production in response to ConA or anti-CD3 MoAb occurred during the course of MAIDS, relative to uninfected controls. " 10/08/1993 - "When interleukin-4 (IL-4)-deficient mice that are defective in Th2 cytokine responses were infected, there was no lethality, and the development of the T cell abnormalities associated with MAIDS was delayed. "

Therapies and Procedures

1.	Immunotherapy 10/01/2004 - "To explore cytokine immunotherapy for sight-threatening AIDS-related human cytomegalovirus (HCMV) retinitis, we developed a mouse model of experimental murine cytomegalovirus (MCMV) retinitis that employs mice with MAIDS, a retrovirus-induced immunodeficiency syndrome. " 04/15/2004 - "We describe successful immunotherapy of murine AIDS (MAIDS) in C57BL/6J mice based on the elimination of replicating CD4(+) regulator T cells. " 05/01/2003 - "However, IL-2 immunotherapy during MAIDS had no appreciable effect on the number of NK cells that infiltrated MCMV-infected eyes. " 05/01/2003 - "We have shown previously that systemic cytokine immunotherapy with interleukin-2 (IL-2) will protect against experimental murine cytomegalovirus (MCMV) in mice with a murine retrovirus-induced immunodeficiency syndrome (MAIDS). " 05/01/2003 - "Taken together, our findings suggest that function of cytotoxic lymphocytes that infiltrate the eye may be more important than absolute numbers of cytotoxic lymphocytes that infiltrate the eye when assessing the protective effects of IL-2 immunotherapy on MCMV retinitis during MAIDS."
2.	Oral Administration 06/01/1995 - "Oral administration of hot water extracts of Chlorella vulgaris (CVE) restored the capacity of MAIDS mice to eliminate L. " 01/01/1997 - "We have previously reported that oral administration of hot water extract of Chlorella vulgaris (CVE) enhances resistance to Listeria monocytogenes through augmentation of Listeria-specific cell-mediated immunity in normal mice and mice with murine acquired immunodeficiency syndrome (MAIDS) caused by murine leukemia virus (MuLV) LP-BM5. " 11/01/1993 - "In an attempt to overcome these limitations, we have tested the efficacy of the oral administration of 2',3'-dideoxycytidine (DDC) and the administration of its phosphorylated derivative, 2',3'-dideoxycytidine 5'-triphosphate (DDCTP) encapsulated into autologous red blood cells in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS). " 01/01/1997 - "In MAIDS mice, oral administration of CVE also augmented the expression of gamma IFN and IL-12 mRNA in the spleen after Listeria infection, while it rather reduced the expression of IL-10 mRNA. " 01/01/2011 - "Among the tested ITCs, oral administration of sulforaphane (SUL), benzyl isothiocyante (BITC), and phenethyl isothiocyanate (PEITC) showed the inhibition of premature death caused by LP-BM5 retrovirus infection, while indolo[3,2-b] carbazole (ICZ) and indole-3-carbinol (I3C) did not delay the progress of the LP-BM5 retrovirus to murine AIDS. "
3.	Ligation 06/01/2006 - "Our laboratory has shown that the interaction of B and CD4 T cells that is central to MAIDS pathogenesis requires ligation of CD154 on CD4 T cells with CD40 on B cells. " 03/30/2007 - "Our lab has shown that the interaction of B and CD4 T cells that is central to MAIDS pathogenesis requires ligation of CD40 on B cells by CD154 on CD4 T cells. " 03/30/2007 - "Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?"
4.	Subcutaneous Injections 01/01/1992 - "Subcutaneous injection of syngeneic mice with trinitrophenyl-modified MAIDS EC resulted in delayed ear swelling responses after challenge that were equivalent to those induced by hapten-modified EC from normal mice, suggesting that the contact sensitivity inducing potential of MAIDS LC was preserved. " 01/01/1997 - "Subcutaneous injection of FK506 (10 mg/kg of body weight) completely blocked the clonal expansion of staphylococcal enterotoxin A (SEA)-reactive T cells in healthy (control) mice after SEA injection but did not disturb it in mice with murine AIDS (MAIDS) caused by infection with LP-BM5 murine leukemia virus. "
5.	Intramuscular Injections 11/01/2002 - "Intramuscular injection of cDNA encoding secretable IL-15 also prevented the development of MAIDS. " 06/01/1997 - "Adult C57BL/6 mice with MAIDS of 8 weeks' duration were treated with either a single intramuscular injection of polyethylene glycol-modified human recombinant IL-2 (PEG-IL-2) or multiple intramuscular injections of murine recombinant IL-12; untreated mice with MAIDS received phosphate-buffered saline. "